Tedizolid

• CAT Number: I005141
• CAS Number: 856866-72-3
• Molecular Formula: C17H15FN6O3
• Molecular Weight: 370.34
• Purity: 98%
• Target: Antibiotic
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C
• IC50: 8.7 μM(MAO-A); 5.7 μM(MAO-B)
• IUPAC Name: (5R)-3-[3-fluoro-4-[6-(2-methyltetrazol-5-yl)pyridin-3-yl]phenyl]-5-(hydroxymethyl)-1,3-oxazolidin-2-one
• InChI: InChI=1S/C17H15FN6O3/c1-23-21-16(20-22-23)15-5-2-10(7-19-15)13-4-3-11(6-14(13)18)24-8-12(9-25)27-17(24)26/h2-7,12,25H,8-9H2,1H3/t12-/m1/s1
• InChIKey: XFALPSLJIHVRKE-GFCCVEGCSA-N
• SMILES: CN1N=C(N=N1)C2=NC=C(C=C2)C3=C(C=C(C=C3)N4CC(OC4=O)CO)F

Tedizolid (CAT: I005141) is an oxazolidinone antibiotic used for the treatment of bacterial infections. It is a second-generation derivative of linezolid with improved pharmacokinetic properties. Tedizolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, specifically targeting the 23S rRNA. It exhibits potent activity against a broad spectrum of Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecium (VRE). Tedizolid has been approved for use in the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible bacteria.

Overview of Clinical Research

Torezolid is an ribosomal protein inhibitor. Tedizolid licensed to Nabriva Therapeutics in USA.

Reference

1: Durkin MJ, Corey GR. New developments in the management of severe skin and deep skin structure infections – focus on tedizolid. Ther Clin Risk Manag. 2015 May 22;11:857-62. doi: 10.2147/TCRM.S64553. eCollection 2015. Review. PubMed PMID: 26045667; PubMed Central PMCID: PMC4447168.
2: Zhanel GG, Love R, Adam H, Golden A, Zelenitsky S, Schweizer F, Gorityala B, Lagacé-Wiens PR, Rubinstein E, Walkty A, Gin AS, Gilmour M, Hoban DJ, Lynch JP 3rd, Karlowsky JA. Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens. Drugs. 2015 Feb;75(3):253-70. doi: 10.1007/s40265-015-0352-7. Review. PubMed PMID: 25673021.
3: Hui Y, Xiaoju L. Tedizolid for treatment of acute bacterial skin and skin structure infections. Expert Rev Anti Infect Ther. 2015;13(9):1051-60. doi: 10.1586/14787210.2015.1073107. Epub 2015 Jul 27. Review. PubMed PMID: 26211946.
4: Locke JB, Zurenko GE, Shaw KJ, Bartizal K. Tedizolid for the management of human infections: in vitro characteristics. Clin Infect Dis. 2014 Jan;58 Suppl 1:S35-42. doi: 10.1093/cid/cit616. Review. PubMed PMID: 24343830.
5: Kanafani ZA, Corey GR. Tedizolid (TR-701): a new oxazolidinone with enhanced potency. Expert Opin Investig Drugs. 2012 Apr;21(4):515-22. doi: 10.1517/13543784.2012.660250. Epub 2012 Feb 13. Review. PubMed PMID: 22324973.